Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07122193 · ClinicalTrials.gov registry record · Phase 3
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
A Phase 3 study of Physiological Effects of Drugs and Peripheral Nervous System Agents, sponsored by Merz North America.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT07122193: Recruiting Phase 3 study of Physiological Effects of Drugs and Peripheral Nervous System Agents, sponsored by Merz North America.
NCT07122193 is a Phase 3 study of Physiological Effects of Drugs and Peripheral Nervous System Agents that is actively recruiting participants, run by Merz North America. The registered enrollment target is 300 participants, roughly in line with the 320-participant average among 6 other Physiological Effects of Drugs trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07122193, a Phase 3 study of Physiological Effects of Drugs and Peripheral Nervous System Agents, is actively recruiting participants, sponsored by Merz North America.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The study will be conducted in two periods: Main Period (MP) and Open label Extension Period (OLEX).
Primary Outcome
MAPS-D is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.
Conditions Studied
Interventions
- DRUG NT 201
- DRUG NT 201 Placebo
Study Locations (20)
Florida
- Merz Investigative Site - Aventura
- Merz Investigative Site - Boca Raton
- Merz Investigative Site - Bradenton
- Merz Investigative Site - Coral Gables
- Merz Investigative Site - Coral Gables
- Merz Investigative Site - West Palm Beach
California
- Merz Investigative Site - Encino
- Merz Investigative Site - Los Angeles
- Merz Investigative Site - Redondo Beach
- Merz Investigative Site - Santa Monica
- Merz Investigative Site - Vista
New York
- Merz Investigative Site - Mount Kisco
- Merz Investigative Site - New York
Arizona
- Merz Investigative Site - Scottsdale
Colorado
- Merz Investigative Site - Greenwood Village
Connecticut
- Merz Investigative Site - Westport
District of Columbia
- Merz Investigative Site - Washington D.C.
Georgia
- Merz Investigative Site - Alpharetta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-08-27 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
What NCT07122193 shows while recruiting
NCT07122193 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 320-participant average among 6 other Physiological Effects of Drugs trials with a reported enrollment target.
The record links to 10 conditions, with Physiological Effects of Drugs appearing as the primary indexed condition, and to 2 interventions - of which NT 201 is the first listed.
NCT07122193 names 20 study sites across 10 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT07122193 about?
NCT07122193 is a clinical study titled "A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States". The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The study will be conducted in two periods: Main Period (MP) and Open label Extension Period (OLEX).
What is the current status of trial NCT07122193?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2025-08-27. Estimated completion is 2028-01.
What conditions does trial NCT07122193 study?
This clinical trial studies the following conditions: Physiological Effects of Drugs, Peripheral Nervous System Agents, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Neuromuscular Agents.
What interventions are being tested in trial NCT07122193?
The interventions under investigation include: NT 201 (DRUG), NT 201 Placebo (DRUG).
Who is sponsoring clinical trial NCT07122193?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07122193 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Physiological Effects of Drugs
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
ACTIVE NOT RECRUITING · Phase 3
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
Natural History of Depression, Bipolar Disorder and Suicide Risk
RECRUITING
-
Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes
COMPLETED · Phase 4
-
Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy
COMPLETED · Phase 4
-
Relative Bioavailability of LY03010 Compared to Listed Drug
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI